title: Preventive effects of low-dose dexamethasone for delayed adverse events induced by carboplatin-based combination chemotherapy.
abstract: We performed a retrospective study to examine the protective effect of low-dose dexamethasone (DEX) on delayed adverse events induced by carboplatin (CBDCA)-based combination chemotherapy in patients with thoracic tumors. Low-dose DEX (4-8 mg/day) was administered on day 1 and after, in addition to a serotonin 5-HT3 receptor antagonist. The acute adverse events (day 1) were well controlled in the patients with or without co-treatment of DEX. On the other hand, the delayed nausea, emesis, anorexia, and fatigue after day 2 failed to be controlled by 5-HT3 antagonist alone. Co-treatment with DEX significantly suppressed the grade of the delayed adverse events during days 2-10. The mean ratio of complete protection during days 2-10 were significantly higher in the DEX-treated group compared with the non-DEX-treated group. These results reveal that low-dose DEX is a clinically effective treatment for the prevention of delayed adverse events induced by CBDCA-based combination chemotherapy.
authors.affiliation: Department of Pharmacy, Kagawa University Hospital, Kagawa, Japan. khitochi@med.kagawa-u.ac.jp
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kawazoe
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Takiguchi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Chiaki
authors.initials: C
authors.lastname: Doi
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Fukuoka
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kanaji
authors.forename: Shuji
authors.initials: S
authors.lastname: Bandoh
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishida
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Houchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000855:Anorexia / Q000139:chemically induced / Q000517:prevention & control; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016190:Carboplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage*; D005221:Fatigue / Q000139:chemically induced / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced* / Q000517:prevention & control*; D012189:Retrospective Studies; D058831:Serotonin 5-HT3 Receptor Antagonists; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D058831:Serotonin 5-HT3 Receptor Antagonists; D003907:Dexamethasone; D016190:Carboplatin